Search

News Comparison of Efficacy of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis and Moderate to Severe Psoriasis

Ixekizumab, a humanized monoclonal antibody against interleukin 17A (IL-17A), is approved in the Czech Republic for the treatment of active psoriatic arthritis (PsA) and moderate to severe plaque psoriasis. Its efficacy compared to adalimumab in PsA was evaluated in the head-to-head SPIRIT-H2H study. A post-hoc analysis of this study focusing on a subpopulation of patients with PsA and concurrent moderate to severe plaque psoriasis was presented at the Congress of the European Academy of Dermatology and Venereology (EADV) in October 2019 in Madrid.

Source: Biological Treatment 9. 5. 2020

News Comparison of the Efficacy and Safety of Two Enoxaparin Dosing Regimens in Patients After Chest Surgery

Effective prevention of thromboembolic disease in patients undergoing chest surgery is one of the key therapeutic goals. However, the question remains as to what dose of low molecular weight heparin is optimal for these individuals. A multicenter clinical trial compared the efficacy of a fixed dose of enoxaparin to a weight-adjusted dose.

Source: Thromboprophylaxis 31. 8. 2020

News Thromboprophylaxis in Cancer Patients −⁠ Results of Current Meta-Analysis

A recently published meta-analysis shows the benefits of thromboprophylaxis in cancer patients, with no increased risk of severe bleeding complications.

Source: Thromboprophylaxis 27. 5. 2020

News Empagliflozin in the Treatment of Patients with Chronic Heart Failure

Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization due to heart failure and the risk of severe renal events in patients with type 2 diabetes mellitus. The efficacy of the SGLT2 inhibitor empagliflozin directly in the treatment of patients with chronic heart failure with reduced ejection fraction was evaluated in the EMPEROR-Reduced clinical study, the recently published results of which we summarize in the following article.

Source: Heart Failure 7. 12. 2021

News Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC

Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant antitumor activity against non-small cell lung cancer (NSCLC). According to the results of an international clinical study published in the Annals of Oncology, it shows very good efficacy in treating intracranial metastases in patients who experienced disease progression during therapy with second-generation ALK inhibitors.

Source: Genetic Profile and Treatment of NSCLC 23. 7. 2021

News Perioperative substitution therapy in patients with vWD must be tailored

Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.

Source: Von Willebrand Disease 25. 8. 2021

News Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease

A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors during surgery in patients with von Willebrand disease (vWD).

Source: Von Willebrand Disease 25. 8. 2021

News Can sartans improve clinical outcomes in hypertensive patients with COVID-19?

Dysfunction of the renin-angiotensin system (RAS) has been detected in patients with COVID-19. This finding led to the hypothesis that RAS inhibitors (RASi) could help these patients. To verify this, a retrospective study was conducted, the results of which we briefly summarize.

Source: Sartans in the Treatment of Hypertension 19. 4. 2021

News Does idarucizumab reverse the anticoagulant effect of dabigatran regardless of renal function?

The drugs idarucizumab and dabigatran are excreted by the kidneys. The RE-VERSE AD study investigated whether the renal function of patients affects the extent of the reversing effect of idarucizumab on the effect of dabigatran.

Source: Anticoagulant Treatment 29. 3. 2021

News New Treatment Option for Metastatic Pancreatic Cancer –⁠ Pegylated Liposomal Irinotecan

The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its potential use in the treatment sequence of metastatic pancreatic ductal adenocarcinoma.

Source: Treatment of Gastrointestinal Carcinomas 11. 5. 2021

News Sport as an Important Part of the Life of Hemophiliacs

People with congenital bleeding disorders have very diverse approaches to sports and exercise. The possibility of preventing bleeding by administering safe and effective medications for these patients clearly supports engagement in an active physical life.

Source: Hemophilia with Movement 7. 4. 2021

News Diabetic Nephropathy and COVID-19: Fatal Connection?

People with diabetes and diabetic kidney disease exhibit higher mortality and risk of severe illness in connection with COVID-19. The worse prognosis of these patients likely has multiple reasons; in the following overview, we will focus mainly on the cellular receptor of the SARS-CoV-2 virus –⁠ angiotensin-converting enzyme 2 (ACE2).

Source: Diabetes 26. 4. 2021

News Efficacy of Panitumumab in the Treatment of Refractory mCRC

A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall response rate compared to controls in patients with refractory metastatic colorectal cancer (mCRC).

Source: Colorectal Cancer 20. 8. 2021

News Impact of Physiotherapy and Sports Activities on the Results of Movement Tests in Children with Hemophilia

At the 9th Hemophilia Academy, held online from October 5-7 in Budapest, a lecture by Mgr. Marie Katzerová from University Hospital Brno titled “Physiotherapy, Sports, and Hemophilia” aimed to elucidate the impact of physical activity on the results of movement tests in children with hemophilia.

Source: Hemophilia with Movement 7. 12. 2021

News Real Impact of Lockdown on Asthma Treatment –⁠ EAACI Survey Results

Restrictions associated with the COVID-19 pandemic have had a significant impact on the treatment of chronic diseases such as asthma. A study published in the journal Allergy focused on evaluating treatment approaches for adult and pediatric patients with asthma during the coronavirus pandemic lockdowns.

Source: Asthma under control 8. 12. 2021